MNPRMonopar Therapeutics Inc. Common Stock — stock analysis & sentiment
Monopar Therapeutics Inc. Common Stock (MNPR) last closed at $108.35, near the top of its 52-week range of $29.18–$116.69. Composite market sentiment across 1 analysis is positive (+33 on a −100 to +100 scale), as of Aug 3, 2026.
Produced by the Synoptiv Research Engine from public financial data. Read the methodology.
Go beyond the overview
The thesis, technical signals, risk levels, and complete evidence — everything the overview leaves out.
What the data says
An overview of the public data behind MNPR.
At $108.35, the stock sits near the upper end of a 52-week range that runs from $29.18 to $116.685 — close to the high, and roughly four times the low. A band that wide over a single year describes a stock that has repriced dramatically rather than drifted, and a beta of 1.475 fits that picture: it has tended to move about half again as much as the broader market in either direction.
The valuation figures reflect a company that is not yet earning money. Forward P/E is negative at about -34.6, which is what happens when the earnings estimate underneath it is a loss rather than a profit, and the reported profit margin is zero. That leaves the price-to-book ratio of roughly 5.4 as the more usable anchor — the market is carrying a roughly $726 million capitalization on a book value several times smaller. In practical terms, the figures show a business valued on what its pipeline might become rather than on current results, which is the standard shape of a clinical-stage biotech's numbers.
The recent news flow is company-specific rather than sector-driven. It splits into three strands: clinical data disclosures, concentrated on ALXN1840 in Wilson disease and presented at EASL 2026, AASLD 2025, and in a Journal of Hepatology letter; routine quarterly and full-year financial reporting through the first quarter of 2026; and capital raising, including a $135 million underwritten offering of common stock and pre-funded warrants priced in September 2025 and a $19.2 million public offering in October 2024. Notably, the headline clinical news over the past year has centered on the Wilson disease program rather than on the radiopharmaceutical candidates described as the lead pipeline.
Written from public market data. Research, not financial advice — the thesis, signals and risk levels are in the full report.
Price chart
MNPR daily price history.
Market sentiment
A composite of the public market data in this analysis, from −100 (bearish) to +100 (bullish).
This gauge blends news tone, analyst views, insider and congressional activity, and price momentum into a single score. The full report breaks down each driver and pairs it with the thesis.
See the full sentiment breakdown in the report →Key stats
A public snapshot of commonly used market and valuation measures.
Valuation & size
- Market cap
- $725.84M
- Enterprise value
- $588.58M
- Forward P/E
- -34.56
- Price / book
- 5.36
Profitability & growth
- Net margin
- 0.00%
Price & risk
- Beta
- 1.48
- Average volume
- 209.53K
From noise to signal. The full report has MNPR’s thesis, trade signal, and risk levels.
About Monopar Therapeutics Inc. Common Stock
Monopar Therapeutics is a clinical-stage biopharmaceutical company based in Wilmette, Illinois, founded in 2014. Its work centers on oncology, with a pipeline built largely around radiopharmaceuticals — drug candidates that pair a targeting molecule with a radioactive isotope for either imaging or treatment. The company's lead program is MNPR-101, a humanized monoclonal antibody directed at the urokinase plasminogen activator receptor (uPAR), a target expressed on a range of advanced solid tumors. MNPR-101 is being developed in conjugated forms: MNPR-101-Zr, an imaging agent paired with zirconium-89, and a radiotherapeutic version paired with a treatment isotope, both in early-stage clinical work. Monopar has also worked with outside partners, including Excel Diagnostics and Nuclear Oncology Center on its MNPR-101 imaging and therapeutic candidates and NorthStar Medical Radioisotopes on radioisotope supply and development, and it previously held rights to ALXN1840, a candidate for Wilson disease licensed from Alexion.
Latest news
Recent headlines related to MNPR, with vendor tone.
MNPR — frequently asked questions
Answered from the public data on this page.
What is the current market sentiment for MNPR?
As of Aug 3, 2026, Monopar Therapeutics Inc. Common Stock (MNPR) carries positive (+33 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.
How has MNPR stock been performing?
Monopar Therapeutics Inc. Common Stock last closed at $108.35, near the top of its 52-week range of $29.18–$116.69.
What is MNPR's market cap and valuation?
Monopar Therapeutics Inc. Common Stock has a market capitalization of about $725.84M.
What sector is MNPR in, and who are its competitors?
Monopar Therapeutics Inc. Common Stock operates in the Healthcare sector, specifically Biotechnology. Comparable companies include KURA, SLDB, DSGN, CADL, AURA.
Where can I find a full analysis of MNPR?
The full MNPR report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.
Analysis history
Every saved analysis, newest first.